神经递质谷氨酸及其抗精神病药物研究进展

被引:11
作者
苏允爱
司天梅
机构
[1] 北京大学精神卫生研究所
[2] 北京大学精神卫生研究所 北京
[3] 北京
关键词
谷氨酸; 精神分裂症; 抗精神病药物; 受体;
D O I
10.13699/j.cnki.1001-6821.2004.03.018
中图分类号
R749.3 [精神分裂症];
学科分类号
100205 ;
摘要
典型和非典型抗精神病药物都对人体的谷氨酸神经传递系统有影响,通过对谷氨酸受体的调节,可开发新的抗精神病药物,这对今后更有效的治疗精神分裂症提供了良好的前景。
引用
收藏
页码:224 / 227
页数:4
相关论文
共 14 条
[1]  
Emerging role of glutamate in the pathophy-siology and treatment of schizophrenia. Goff DC,Coyle JT. American Journal of Psychiatry . 2001
[2]  
Amelioration of negative symptoms in schizophrenia by glycine. Javitt DC,Zylberman I,Zukin SR,et al. American Journal of Psychiatry . 1994
[3]  
Low cerebrospinal fluidglutamate in schizophrenic patients and a new hypothesis onschizophrenia. Kim JS,Kornhuber HH,Schmid BW,et al. Neuroscience Letters . 1980
[4]  
Glutamate receptor expression inschizophrenic brain. Meador-woodrutf JH,Healy DJ. Brain Research Reviews . 2000
[5]  
Molecular aspects of glutamate dysregula- tion:implications for schizophrenia and its treataieot. Christine K,Stephan H. Pharmacology and Therapeutics . 2003
[6]  
Regulation of NMDA Receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Riva MA,Tascedda F,Lovati E,et al. Molecular Brain Research . 1997
[7]  
Abnormal excitatoryneurotransmitter metabolism in schizophrenic brains. Tsai G,Passani LA,Slusher BS,et al. Archives of General Psychiatry . 1995
[8]  
D-cycloserine added to risperidone in patients with primary negative symptoms in schizo-phrenia. Evins AE,Amico ED,Posever TA,et al. Schizophrenia Research . 2002
[9]  
Regulation of ionotropicglutamate receptors in the rat brain in response to the atypicalantipsychotic seroquel (quetiapine fumarate). Tascedda F,lovati E,Blom JMC,et al. Neuropsychopharmacology . 1999
[10]  
Modulation of glutamatereceptors in response to the novel antipsychotic olanzapine inrats. Fabio T,John MC,Blom NB,et al. Biological Psychiatry . 2001